The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase
- 1 October 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 1 (5), 369-375
- https://doi.org/10.1158/1940-6207.capr-08-0081
Abstract
Population studies provide evidence that obesity and insulin resistance are associated not only with elevated serum insulin levels and reduced serum adiponectin levels but also with increased risk of aggressive prostate and colon cancer. We show here that adiponectin activates AMP-activated protein kinase (AMPK) in colon (HT-29) and prostate (PC-3) cancer cells. These results are consistent with prior observations in myocytes, but we show that in epithelial cancer cells AMPK activation is associated with reduction in mammalian target of rapamycin activation as estimated by Ser2448 phosphorylation, with reduction in p70S6 kinase activation as estimated by Thr389 phosphorylation, with ribosomal protein S6 activation as estimated by Ser235/236 phosphorylation, with reduction in protein translation as estimated by [35S]methionine incorporation, and with growth inhibition. Adiponectin-induced growth inhibition is significantly attenuated when AMPK level is reduced using small interfering RNA, indicating that AMPK is involved in mediating the antiproliferative action of this adipokine. Thus, adiponectin has the characteristics of a AMPK-dependent growth inhibitor that is deficient in obesity, and this may contribute to the adverse effects of obesity on neoplastic disease. Furthermore, metformin was observed to activate AMPK and to have growth inhibitory actions on prostate and colon cancer cells, suggesting that this compound may be of particular value in attenuating the adverse effects of obesity on neoplasia.Keywords
This publication has 32 references indexed in Scilit:
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 levelOncogene, 2008
- Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathwayEndocrine-Related Cancer, 2007
- Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer CellsCancer Research, 2006
- mTOR, translation initiation and cancerOncogene, 2006
- Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome?Diabetes, Obesity and Metabolism, 2006
- AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolismCell Metabolism, 2005
- Adiponectin: More Than Just Another Fat Cell Hormone?Diabetes Care, 2003
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsThe New England Journal of Medicine, 2003
- AMP-activated Protein Kinase Suppresses Protein Synthesis in Rat Skeletal Muscle through Down-regulated Mammalian Target of Rapamycin (mTOR) SignalingOnline Journal of Public Health Informatics, 2002
- Obesity and insulin resistanceJCI Insight, 2000